89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89-100, is being developed for the treatment of NASH and for the treatment of SHTG with ongoing proof of concept studies in both indications. BIO89-100 is a specifically engineered glycoPEGylated analog of FGF21. 89bio is headquartered in San Francisco with operations in Herzliya, Israel.
Sep 23, 2020 10:35 PM EDT
Data Provided by Refinitiv. Minimum 15 minutes delayed.